Genmab A/S | Balance Sheet

Fiscal year is January-December. All values DKK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,557
2,661
3,493
3,922
5,423
6,106
Total Accounts Receivable
136
106
175
976
637
1,327
Total Current Assets
1,693
2,766
3,668
4,898
6,059
7,433
Net Property, Plant & Equipment
23
26
29
32
113
162
Long-Term Note Receivable
6
6
7
1
9
10
Intangible Assets
3
63
193
182
124
470
Total Assets
1,732
2,867
3,903
5,238
6,603
8,461
ST Debt & Current Portion LT Debt
-
-
2
-
-
Accounts Payable
-
-
32
22
41
Income Tax Payable
-
-
-
62
-
Other Current Liabilities
905
656
382
328
286
Total Current Liabilities
908
656
414
412
327
Long-Term Debt
-
-
-
-
-
Provision for Risks & Charges
1
1
1
-
1
Deferred Taxes
7
6
6
125
297
Other Liabilities
163
176
-
-
2
Total Liabilities
1,072
834
416
412
331
Common Equity (Total)
660
2,033
3,487
4,827
6,272
Total Shareholders' Equity
660
2,033
3,487
4,827
6,272
Total Equity
660
2,033
3,487
4,827
6,272
Liabilities & Shareholders' Equity
1,732
2,867
3,903
5,238
6,603

About Genmab A/S

View Profile
Address
Kalvebod Brygge 43
Copenhagen CR 1560
Denmark
Employees -
Website http://www.genmab.com
Updated 07/08/2019
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer. Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX.